Janus kinase 2

Nitrase Therapeutics Announces Publication in the Journal of Biological Chemistry on the Role of Tyrosine Nitration in Cell Signaling and Cancer Biology

Retrieved on: 
星期四, 七月 13, 2023
DAMP, Biochemistry, Database, Nitration, STAT1, Tyrosine, Phosphorylation, HER2, Hsps, CCL2, Bioorganic chemistry, Enzyme, Cancer, CXCL12, Sirtuin 2, LCK, Human, SHP2, DSM-IV codes, BCL2, Protein, Journal, B cell, HDAC2, Cell, Drug discovery, JAK2, Histone deacetylase 2, Sirtuin 6, Therapy, Janus kinase 2, SIRT6, SIRT2, Medical imaging

Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.

Key Points: 
  • Nitration and phosphorylation overlapped in 879 tyrosine residues in 460 proteins.
  • The analysis revealed three major cellular networks that could be impacted by tyrosine nitration, resulting in altered protein function, localization, turnover, and protein-protein interactions.
  • Known sites of tyrosine nitration are also sites of phosphorylation, suggesting an extensive role for nitration in cell signaling, such that tyrosine nitration could profoundly interfere or alternatively complement tyrosine phosphorylation.
  • Tyrosine nitration is associated with different types of cancer by altering metabolic reprogramming and signaling.

NS Pharma Announces Receipt of Orphan Drug Designation from the U.S. FDA for NS-018, an Investigational Treatment for Myelofibrosis

Retrieved on: 
星期二, 十二月 20, 2022
Spleen, Patient, Mutation, Lymphatic system, Bone marrow, Disease, JAK2, FDA, Janus kinase 2, Fatigue, Ruxolitinib, Bone pain, Fever, Survival, MF, Splenomegaly, Orphan, Woman, Abdominal pain, Pharmaceutical industry, Janus

PARAMUS, N.J., Dec. 20, 2022 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), today announced that the U.S. FDA has granted Orphan Drug Designation to NS-018 (ilginatinib), an investigational treatment for myelofibrosis (MF), a rare and incurable blood cancer.

Key Points: 
  • PARAMUS, N.J., Dec. 20, 2022 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), today announced that the U.S. FDA has granted Orphan Drug Designation to NS-018 (ilginatinib), an investigational treatment for myelofibrosis (MF), a rare and incurable blood cancer.
  • The FDA issues Orphan Drug Designations to support the development and evaluation of new treatments to prevent, diagnose, or treat a rare disease or condition.
  • NS Pharma, Inc., is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. For more information, please visit http://www.nspharma.com .
  • NS Pharma is a registered trademark of the Nippon Shinyaku group of companies.

BESREMi® (ropeginterferon alfa-2b-njft) Now Approved for the Treatment of Adults with Polycythemia Vera

Retrieved on: 
星期四, 十一月 18, 2021
Oncology, FDA, Health, Genetics, Clinical Trials, Pharmaceutical, Janus, Patient, JAK2, Regulation of tobacco by the U.S. Food and Drug Administration, Janus kinase 2, CHR, Diagnosis, Prevalence, Thrombosis, Time-invariant system, Blood, National Comprehensive Cancer Network, Physician, Treatment, Survival, Polycythemia, Adult, United, FDA, Myeloproliferative neoplasm, NCCN, Interferon alfa-2b, Classification, Specialty pharmacy, Food, Pharmaceutical industry

Onco360 is honored to become a specialty pharmacy provider for BESREMi patients, said Benito Fernandez, Chief Commercial Officer, Onco360.

Key Points: 
  • Onco360 is honored to become a specialty pharmacy provider for BESREMi patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • We are committed to supporting the highly specialized needs of polycythemia vera patients and their physicians across the United States.
  • The prevalence of polycythemia in the United States is approximately 148,000 cases.1 Polycythemia vera results from abnormal red blood cell proliferation due to genetic mutations involving the Janus Kinase 2 (JAK2) gene.
  • The median overall survival for patients diagnosed with polycythemia vera is approximately 20 years.3
    BESREMi is manufactured by PharmaEssentia, a growing biopharmaceutical innovator based in Taiwan.

 Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline

Retrieved on: 
星期四, 八月 5, 2021
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Momelotinib, MD, Fast Track, Jak, U.S. Securities and Exchange Commission, Webcast, Bachelor of Medicine, Bachelor of Surgery, Anemia, Disease, Private Securities Litigation Reform Act, Security (finance), Development, Cancer, Janus kinase 1, Patient, Bromodomain-containing protein 3, COVID-19, BRD4, ACVR1, Splenomegaly, SEC, Symptoms of COVID-19, Risk, BRD2, Doctor of Philosophy, Janus kinase 2, Research, BRDT, Primary myelofibrosis, Safety, Ruxolitinib, Conference, BET, Nasdaq, International, Pharmaceutical industry, Momelotinib, Sierra Oncology, MOMELOTINIB, SIERRA ONCOLOGY

Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022.

Key Points: 
  • Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022.
  • First, it brings another novel compound into the Sierra development pipeline, expanding our opportunity to deliver transformative therapies for patients with rare cancers.
  • Several BET inhibitors are under clinical investigation in multiple solid tumor and hematologic indications, including myelofibrosis.
  • AZD5153 is a selective BRD4 inhibitor with a novel bivalent binding mode that inhibits both protein bromodomains, resulting in improved potency.

Insights on the Myeloproliferative Neoplasm Drugs Global Market to 2027 - Featuring Gamida Cell, Sierra Oncology & CTI BioPharma Among Others - ResearchAndMarkets.com

Retrieved on: 
星期一, 六月 28, 2021
Pharmaceutical, Health, Oncology, Tyrosine kinases, Myeloproliferative neoplasm, Janus kinase 2, Tyrosine kinase inhibitor, Cancer, Janus kinase inhibitor, Neoplasms

The "Myeloproliferative Neoplasm Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myeloproliferative Neoplasm Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The various drug classes indicated for the treatment of myeloproliferative neoplasm are demethylation agents, tyrosine kinase inhibitor, multikinase inhibitors, JAK2 inhibitor, and others.
  • Key companies are focusing on strategies such as mergers and acquisitions, which is expected to drive the global myeloproliferative neoplasm drugs market growth.
  • Moreover, key players are focusing on product launches and product approvals to strengthen their presence in the global myeloproliferative neoplasm drugs market.

Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis

Retrieved on: 
星期五, 二月 19, 2021
Science, Biotechnology, Research, Pharmaceutical, Managed care, Health, FDA, Clinical trials, Chemical compounds, Type I hypersensitivity, Organic compounds, Pyrazoles, Autoimmune diseases, Cyclopentanes, Ruxolitinib, Atopic dermatitis, Dermatitis, Janus kinase 2, Incyte, Atopy

Primary efficacy and safety results from both TRuE-AD trials were presented at the Revolutionizing Atopic Dermatitis Virtual Symposium in April 2020.

Key Points: 
  • Primary efficacy and safety results from both TRuE-AD trials were presented at the Revolutionizing Atopic Dermatitis Virtual Symposium in April 2020.
  • Incyte submitted a priority review voucher (PRV) along with the NDA application for ruxolitinib cream.
  • Ruxolitinib cream is a proprietary formulation of Incytes selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application.
  • Ruxolitinib cream is currently in Phase 3 development for the treatment of atopic dermatitis (TRuE-AD) and for the treatment of adolescents and adults with vitiligo (TRuE-V).

Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting

Retrieved on: 
星期六, 十二月 5, 2020
Clinical medicine, Medicine, Tyrosine kinases, Primary myelofibrosis, Health, Momelotinib, Janus kinase 2, Targeted therapy, Thrombopoietin receptor, Jak, Cancer

"Momelotinib's unique mechanism of actiontargeting JAK1, JAK2 and ACVR1is translating to durability of activity and survival data consistent with its clinical and biologic profile," said Dr. Verstovsek.

Key Points: 
  • "Momelotinib's unique mechanism of actiontargeting JAK1, JAK2 and ACVR1is translating to durability of activity and survival data consistent with its clinical and biologic profile," said Dr. Verstovsek.
  • "As the SIMPLIFY data sets continue to mature, we are seeing increasingly exciting outcomes in terms of overall survival, as well as myelofibrosis disease hallmarks, including splenic response and transfusion independence," said Barbara Klencke, MD, Chief Development Officer at Sierra Oncology.
  • Momelotinib is a selective and orally bioavailable JAK1, JAK2 and ACVR1 inhibitor currently under investigation for the treatment of myelofibrosis.
  • Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer.

Sierra Oncology to Host KOL Panel Event to Discuss Updated Phase 3 Myelofibrosis Data Presented at ASH

Retrieved on: 
星期二, 十二月 1, 2020
Clinical medicine, Medicine, Nitriles, Tyrosine kinases, Benzamides, Momelotinib, Morpholines, Targeted therapy, Primary myelofibrosis, Health, Janus kinase 2, Oncology

The presentation will be webcast live, and an archive of the presentation will be accessible after the event through the Sierra Oncology website: www.SierraOncology.com .

Key Points: 
  • The presentation will be webcast live, and an archive of the presentation will be accessible after the event through the Sierra Oncology website: www.SierraOncology.com .
  • Momelotinib is a selective and orally bioavailable JAK1, JAK2 and ACVR1 inhibitor currently under investigation for the treatment of myelofibrosis.
  • Momelotinib is currently under investigation in the MOMENTUM clinical trial, a global, randomized, double-blind Phase 3 study for symptomatic and anemic myelofibrosis patients.
  • Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer.

Pooled Results from Incyte’s TRuE-AD1 and TRuE-AD2 Atopic Dermatitis Studies of Ruxolitinib Cream Show Clinically Meaningful Improvements in Patient-Reported Quality of Life Assessments

Retrieved on: 
星期四, 十月 29, 2020
Biotechnology, General Health, Pharmaceutical, Health, Chemical compounds, Organic compounds, Pyrazoles, Cyclopentanes, Nitriles, Ruxolitinib, Autoimmune diseases, Dermatitis, Atopic dermatitis, Janus kinase 2, Janus kinase inhibitor, Atopic Dermatitis, TRuE-AD, Ruxolitinib Cream, Incyte Dermatology, Incyte

The overall safety profile of ruxolitinib cream was consistent with previously reported data, with no new safety signals observed in this pooled analysis.

Key Points: 
  • The overall safety profile of ruxolitinib cream was consistent with previously reported data, with no new safety signals observed in this pooled analysis.
  • Atopic dermatitis (AD) is a common chronic and intensely pruritic disease characterized by inflammation of the skin.
  • The studies have also been tracking the frequency, duration and severity of adverse events associated with the use of ruxolitinib cream.
  • Ruxolitinib cream is a proprietary formulation of Incytes selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application.

Sierra Oncology Appoints Christina Thomson as General Counsel

Retrieved on: 
星期二, 七月 28, 2020
Nitriles, Tyrosine kinases, Benzamides, Momelotinib, Morpholines, Janus kinase 2, Myelofibrosis, General counsel, Cancer, Clinical medicine, Chemistry

VANCOUVER, British Columbia, July 28, 2020 (GLOBE NEWSWIRE) -- Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced the appointment of Christina Thomson as General Counsel.

Key Points: 
  • VANCOUVER, British Columbia, July 28, 2020 (GLOBE NEWSWIRE) -- Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced the appointment of Christina Thomson as General Counsel.
  • Christina is a highly effective General Counsel with a wealth of business and legal expertise, including corporate and competitive strategy, licensing, and commercialization planning.
  • Christina Thomson is a seasoned legal executive who has served as General Counsel for several public, private and non-profit life sciences companies, including Athira Pharma, Infectious Disease Research Institute, APT Pharmaceuticals and Avigen, in addition to representing clients in private practice.
  • Sierra Oncology granted an equity award on July 28, 2020 to Christina Thomson as a material inducement to her employment as General Counsel with the Company.